Cited by 945Liver Disease Diagnosis and TreatmentLiver Disease and TransplantationLiver Diseases and Immunity

Age as a confounding factor for the accurate non-invasive diagnosis of advanced NAFLD fibrosis

Open access
McPherson, Stuart, Hardy, Tim, Dufour, Jean-Francois, Petta, Salvatore, Romero-Gomez, Manuel, Allison, Mike, Oliveira, Claudia P, Francque, Sven +8 more·2017·American Journal of Gastroenterology

Abstract

OBJECTIVES: Non-invasive fibrosis scores are widely used to identify/exclude advanced fibrosis in patients with non-alcoholic fatty liver disease (NAFLD). However, these scores were principally developed and validated in patients aged between 35 and 65 years of age. The objective of this study was to assess the effect of age on the performance of non-invasive fibrosis tests in NAFLD. METHODS: Patients were recruited from European specialist hepatology clinics. The cohort was divided into five age-based groups: ≤35 (n=74), 36-45 (n=96), 46-55 (n=197), 56-64 (n=191), and ≥65 years (n=76), and the performance of the aspartate aminotransferase (AST)/alanine transaminase (ALT) ratio, fibrosis 4 (FIB-4), and NAFLD fibrosis score (NFS) for advanced fibrosis (stage F3-F4) for each group was assessed using liver biopsy as the standard. RESULTS: Six hundred and thirty-four patients were included. The diagnostic accuracy of the AST/ALT ratio was lower than NFS and FIB-4 in all the age groups. The AST/ALT ratio, NFS, and FIB-4 score performed poorly for a diagnosis of advanced fibrosis in those aged ≤35 years (area under the receiver operating characteristic curves (AUROCs 0.52, 0.52, and 0.60, respectively). For all groups >35 years, AUROCs for advanced fibrosis were similar for the NFS and FIB-4 score (range 0.77-0.84). However, the specificity for advanced fibrosis using the FIB-4 and NFS declined with age, becoming unacceptably low in those aged ≥65 years (35% for FIB-4 and 20% for NFS). New cutoffs were derived (and validated) for those aged ≥65 years, which improved specificity to 70% without adversely affecting sensitivity (FIB-4 2.0, sensitivity 77%; NFS 0.12, sensitivity 80%). CONCLUSIONS: The NFS and FIB-4 scores have similar accuracy for advanced fibrosis in patients aged >35 years. However, the specificity for advanced fibrosis is unacceptably low in patients aged ≥65 years, resulting in a high false positive rate. New thresholds for use in patients aged ≥65 years are proposed to address this issue.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/ajg.2016.453

Cites

53 of 53 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 1

  1. Vallet-Pichard A, Mallet V, Nalpas B et al. FIB-4: an inexpensive and accurate marker of fibrosis in HCV infection. comparison with liver biopsy and fibrotest. Hepatology 2007; 46: 32–36. 17567829

Cited by

Sorted by citations

Authors
McPherson, S., Hardy, T., Dufour, J.-F., Petta, S., Romero-Gomez, M., Allison, M., Oliveira, C. P., Francque, S., Van Gaal, L., Schattenberg, J. M., Tiniakos, D., Burt, A., Bugianesi, E., Ratziu, V., Day, C. P., & Anstee, Q. M.
Affiliations
  • Freeman Hospital (GB)
  • University of Palermo (IT)
  • Addenbrooke's Hospital (GB)
  • Universidade de São Paulo (BR)
  • Antwerp University Hospital (BE)
  • University Medical Center of the Johannes Gutenberg University Mainz (DE)
  • The University of Adelaide (AU)
  • Azienda Ospedaliera Citta' della Salute e della Scienza di Torino (IT)
  • Pitié-Salpêtrière Hospital (FR)
Corresponding author
Anstee, Quentin M
Venue
American Journal of Gastroenterology
Published
2017-05
Volume
112
Issue
5
Pages
740-751
ISSN
0002-9270 (ISSN-L)
OpenAlex
W2529917894
Cited by
945
References
53
Citations by year
2026: 129 · 2025: 150 · 2024: 123 · 2023: 126 · 2022: 108 · 2021: 125 · 2020: 79 · 2019: 49 · 2018: 24 · 2017: 22 · 2016: 1 · 2015: 3
FWCI
30.01
Type
journal article
Language
en
Open access
Licence
cc-by-nc-sa
Locations
  • The American Journal of Gastroenterology (publishedVersion)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-sa)
  • PubMed Central (publishedVersion, cc-by-nc-sa)
  • PubMed (publishedVersion)
  • RISalud Institutional Health Repository of Andalucía (submittedVersion, cc-by-nc-sa)
  • Institutional Research Information System University of Turin (University of Turin) (submittedVersion, other-oa)
  • Bern Open Repository and Information System (University of Bern) (submittedVersion, cc-by-nc-sa)
  • Adelaide Research & Scholarship (AR&S) (University of Adelaide) (submittedVersion, cc-by-nc-sa)
  • Nova Science Publishers (Nova Science Publishers, Inc.) (submittedVersion, other-oa)
  • Newcastle University ePrints (Newcastle Univesity) (cc-by-nc-sa)
  • Open Access CRIS of the University of Bern
Funders
  • European Commission (634413, HORIZON2020)
  • European Association for the Study of the Liver
Topics
  • Health Sciences › Medicine › Epidemiology › Liver Disease Diagnosis and Treatment
  • Health Sciences › Medicine › Hepatology › Liver Disease and Transplantation
  • Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
Keywords
non-alcoholic fatty liver disease, liver fibrosis, advanced fibrosis, non-invasive fibrosis scores, NAFLD fibrosis score, FIB-4, AST/ALT ratio, elderly patients, false positive rate, confounding factor, transient elastography
MeSH terms
Adult, Age Factors, Aged, Alanine Transaminase, Aspartate Aminotransferases, Biopsy, False Positive Reactions, Female, Humans, Liver, Liver Cirrhosis, Male, Middle Aged, Platelet Count, Predictive Value of Tests, Reference Values, ROC Curve, Area Under Curve, Non-alcoholic Fatty Liver Disease

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review